Bella Thornton-Clark

Contact Me Today

Bella regularly advises companies ranging from early stage start-ups to late stage unicorns on a wide range of corporate matters. Bella started her career as a venture capital lawyer in San Francisco before moving to London. Her clients value her commercial insight into trends and norms in the Californian start-up market. Bella's practice is focused on technology start-ups with particular emphasis on consumer goods, SaaS, healthcare, and fintech.

Over the past 10 years, we've built a trusted legal team in San Francisco, focused on technology, media and communciation, life sciences and healthcare, real estate, private wealth, and private equity. Supported by colleagues in the UK and Europe, we also offer deep expertise in M&A, international growth, commercial deals, and data privacy.

Find out more

CV

Since 2024 Senior Associate, Taylor Wessing

2022 - 2024 Associate, Taylor Wessing

2020 - 2022 Associate, Gunderson Dettmer, San Francisco

Career

Since 2024 Senior Associate, Taylor Wessing

2022 - 2024 Associate, Taylor Wessing

2020 - 2022 Associate, Gunderson Dettmer, San Francisco

Education

2019 Admission to California Bar

2019 J.D. University of Texas School of Law

Experience

Blue Earth Therapeutics on the closing of US$76.5 million Series A funding

We have advised Blue Earth Therapeutics and its management on the closing of US$76.5 million Series A funding. The new funding comes from a broad spectrum of experienced biotech investors and enables Blue Earth Therapeutics to further advance its clinical stage prostate-specific membrane antigen-targeted radioligand therapies.

Press release

Ross McNaughton

Bella Thornton-Clark

Advising gene therapy company AlveoGene on its complex spinout and launch investment

We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.

Press release

Ross McNaughton

Bella Thornton-Clark

Bella 's news & insights

View Bella 's insights

Click here to find out more

Corporate/M&A & capital markets

Advising Lingotto on its extended Series A funding into Optalysys to US$60 million

6 February 2026

by multiple authors

Corporate/M&A & capital markets

Advising EpilepsyGTx on its US$33 million Series A financing

10 December 2025

by multiple authors

Click here to find out more

Corporate/M&A & capital markets

Advising on £40 million growth investment into Osprey Flight Solutions

9 September 2025

by multiple authors

Click here to find out more

Bella Thornton-Clark

Expertise

Services and Groups

Sectors

CV

Career

Education

Experience

Blue Earth Therapeutics on the closing of US$76.5 million Series A funding

Advising gene therapy company AlveoGene on its complex spinout and launch investment

Bella 's news & insights

Advising Lingotto on its extended Series A funding into Optalysys to US$60 million

Bella Thornton-Clark

Expertise

Services and Groups

Sectors

CV

Career

Education

Experience

Blue Earth Therapeutics on the closing of US$76.5 million Series A funding

Advising gene therapy company AlveoGene on its complex spinout and launch investment

Bella 's news & insights

Advising Lingotto on its extended Series A funding into Optalysys to US$60 million

Related news & insights

Taylor Wessing strengthens Corporate/M&A practice with Equity Partner Jan Hückel

German Federal Court of Justice promotes Legal Certainty for Leaver Clauses in Management Equity Programs in the Private Equity Sector

Carbon Border Adjustment Mechanism (CBAM): From Reporting to Real Financial Impact

Request for a Preliminary Ruling by Federal Court of Justice on the Prohibition of Advertising for Remote Medical Treatments under Section 9 HWG

Sustainability Stories: Notpla

EU Inc. – The 28th Regime: How the European Commission intends to revolutionise the formation of companies

Consumer and Retail in the News

Prediction Markets in Germany and Europe: Legal Status, Risks, and Opportunities

Investing in the German Audit and Tax Advisory Market – Opportunity Amid Regulatory Debate

More Than Share and Asset Deals: Innovative Transaction Structures for MedTech Companies

Related people

Meet me at